A Randomized Prospective Multicentre Trial of Cefpirome Versus Piperacillin-Tazobactam in Febrile Neutropenia

References

• Hughes W. T., Armstrong D., Bodey G. P., Brown A. E., Edwards J. E., Feld R., Pizzo P., Rolston K. V.I., Shenep J. L., Young L S. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin. Infect. Dis. 1997; 25: 551–573
   PubMed Web of Science ®Google Scholar
• Cordonnier C., Herbrecht R., Pico J. L., Gardembas M., Dehner A., Delain M., Moreau P., Ladeb S., Nalet V., Rollin C., Gres J J. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. Clin. Infect. Dis. 1997; 24: 41–51
   PubMed Web of Science ®Google Scholar
• Cometta A., Zinner S., De Bock R., Calandra T., Gaya H., Klastersky J., Langenaeken J., Paesmans M., Viscoli C., Glauser M P. Piperacillin/tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob. Agents Chemother. 1995; 39: 445–452
   PubMed Web of Science ®Google Scholar
• Marie J. P., Vekhoff A., Cony-Makhoul P., Fiere D., Guy H., Herbrecht R., Milpied N., Pico J. L., Plantier I. Piperacillin/tazobactam plus amikacin versus ceftazidime plus amikacin in neutropenic patients with fever. An open multicentric trial. Presse Med. (Paris) 1995; 24: 397–401
   PubMed Web of Science ®Google Scholar
• Wiseman L. R., Lamb H M. Cefpirome. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia. Drugs 1997; 54: 117–140
   PubMed Web of Science ®Google Scholar
• Comité de l'antibiogramme de la Société Française de Microbiologie. Communiqué. Pathol. Biol. (Paris) 1994; 42: 1–8
   PubMedGoogle Scholar
• Bodey G. P., Buckley M., Sathe J. S., Freireich E J. Quantitative relationship between circulating leucocytes and infection in patients with acute leukemia. Ann. Intern. Med. 1966; 64: 328–340
   PubMed Web of Science ®Google Scholar
• Pizzo P A. Management of fever in patients with cancer and treatment-induced neutropenia. N. Engl. J. Med. 1993; 328: 1323–1332
   PubMed Web of Science ®Google Scholar
• Harbarth S., Beeler I., Viot M., Szucs T D. Resource implications of febrile neutropenia in cancer patients. An international collaborative study. Support. Care Cancer 1999; 7: 343–346
   PubMed Web of Science ®Google Scholar
• Bochud P. Y., Calandra T., Francioli P. Bacteremia due to viridans streptococci in neutropenic patients: a review. Am. J. Med. 1994; 97: 256–264
   PubMed Web of Science ®Google Scholar
• Escande M. C., Herbrecht R. Prospective study of bacteraemia in cancer patients. Results of a French multicentre study. Support. Care Cancer 1998; 6: 273–280
   PubMed Web of Science ®Google Scholar
• Dranitsaris G. Clinical and economic considerations of empirical antibacterial therapy of febrile neutropenia in cancer. Pharmacoeconomics 1999; 16: 343–353
   PubMed Web of Science ®Google Scholar
• Pizzo P. A., Hathorn J. W., Hiemenz J., Browne M., Commers J., Cotton D. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N. Engl. J. Med. 1986; 315: 552–558
   PubMed Web of Science ®Google Scholar
• Sanders J. W., Powe N. R., Moore R D. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis. J. Infect. Dis. 1991; 164: 907–916
   PubMed Web of Science ®Google Scholar
• Freifeld A. G., Walsh T., Marshall D., Gress J., Steinberg S. M., Hathorn J., Rubin M., Jarosinski P., Gill V., Young R. C., Pizzo P A. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J. Clin. Oncol. 1995; 13: 165–176
   PubMed Web of Science ®Google Scholar
• Ramphal R. Is monotherapy for febrile neutropenia still a viable alternative? Clin. Infect. Dis. 1999; 29: 508–514
   Google Scholar
• Marie J. P., Marjanovic Z., Vekhoff A., Bouvet A., Chast F., Levy V., Baudard M., Legrand O., Rio B., Delmer A., Zittoun R. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for severely neutropenic patients. Support. Care Cancer 1999; 7: 89–94
   PubMed Web of Science ®Google Scholar
• Wang F. D., Liu C. Y., Hsu H. C., Gau J. P., Chan W. K., Haung M. L., Ho C H. A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients. Chemotherapy 1999; 45: 370–379
   PubMed Web of Science ®Google Scholar
• Marie J. P., Vekhoff A., Pico J. L., Guy H., Andremont A., Richet H. Neutropenic infections: a review of the French Aplasia Study Group in 608 febrile neutropenic patients. J. Antimicrob. Chemother. 1998; 41(Suppl D): 57–64
   PubMed Web of Science ®Google Scholar
• Rozdzinski E., Kern W. V., Reichle A., Moritz T., Schmeiser T., Gaus W., Kurrle E. Once-daily versus thrice-daily dosing of netilmicin in combination with B-lactam antibiotics as empirical therapy for febrile neutropenic patients. J. Antimicrob. Chemother. 1993; 31: 585–598
   PubMed Web of Science ®Google Scholar
• Mayordomo J. I., Rivera F., Diaz-Puente M. T., Lianes P., Colomer R., Lopez-Brea M., Lopez E., Paz-Ares L., Hitt R., Garcia-Ribas I., Cubedo R., Alonso S., Cortes-Funes H. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J. Nat. Cancer Inst. 1995; 87: 803–808
   PubMed Web of Science ®Google Scholar
• Mebis J., Goosens H., Bruyneel P., Sion J. P., Meeus I., Van Droogenbroeck J., Schroyens W., Berneman Z N. Decreasing antibiotic resistance of enterobacteriaccae by introducing a new antibiotic combination therapy for neutropenic fever patients. Leukemia 1998; 12: 1627–1629
   PubMed Web of Science ®Google Scholar
• Dominguez E. A., Smith T. L., Reed E., Sanders C. C., Sanders W. E. A pilot study of antibiotic cycling in a hematology-oncology unit. Infect. Control Hosp. Epidemiol. 2000; 21: S1–4
   Web of Science ®Google Scholar
• Rolston K V. New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clin. Infect. Dis. 1999; 29: 515–521
   PubMed Web of Science ®Google Scholar
• Malik I. A., Khan W. A., Karim M., Aziz Z., Khan M A. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am. J. Med. 1995; 98: 224–231
   Google Scholar
• De Lalla F. Antibiotic treatment of febrile episodes in neutropenic cancer patients. Clinical and economic considerations. Drugs 1997; 53: 789–804
   PubMed Web of Science ®Google Scholar